source
- Alkermes' narcolepsy Phase 3 success; Boehringer's antibody dealPlus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…Endpoints · 2mo ago↗ source
- GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.onclive · 2mo ago↗ source
- FDA Finalizes Food Chemical Safety Post-Market Assessment Program, Launches Reassessment of BHT, ADAFDA continues to implement its bold food agenda, with two decisive actions focused on food chemical safety.fda press · 2mo ago